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Abstract 
Purpose: To explore the literature regarding prevalance, risk factors and the involvement of 
antihypertensive drugs in erectile dysfunction (ED). 
Methods: Original research articles, reviews, editorials and case reports published in English language 
on the prevalence of sexual/erectile dysfunction in hypertensive men taking antihypertensive drugs and 
risk factors were identified through a search of four bibliographic databases, namely, PubMed, 
EMBASE, CINAHL and EBSCO Health. 
Results: Recent analyses suggest that hypertensive men of almost all age groups suffer from ED but it 
is more prevalent in elderly male patients. The involvement of β-blockers was found to be controversial. 
Nevertheless, some evidence had been found regarding the use of propranolol in high doses.  
Conclusion: The present review indicates the need for research to unravel the role of β-blockers in the 
manifestation of ED in hypertensive males, whom there are no contributory factors such as sedentary 
lifestyle, aging, stress and anxiety, etc. 
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Hypertension (blood pressure > 140/90 mm Hg) 
is managed by a number drugs of different 
pharmacological groups. The treatment often 
requires the use of multiple drugs in combination. 
However, antihypertensive drugs such as 
diuretics, potassium sparring diuretics and β-
blockers are believed in to be involved in erectile 
dysfunction (ED) [1,2]. ED refers to diminished 
libido, erectile failure (inability of achieving and/or 
maintaining sufficient penile erection for 
intercourse) and different types of ejaculatory 
problems [3]. This disorder has a negative impact 
on lowering blood pressure [4-6]. The fear of ED 
and its manifestation leads to emotional 
disturbances and noncompliance to the therapy, 
thus affecting patient’s health [7, 8]. Therefore, 
the present article focused in exploring the facts 
regarding the prevalence, risk factors and 
involvement of antihypertensive drugs. The 
literature review indicated several reports about a 
significant prevalence of the dysfunction in 
normal population. 
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The present review of literature was carried out 
to respond to the question, ‘are there any clear, 
demonstrable and meaningful relationship 
between the use of antihypertensive drugs and 
manifestation of ED’? By doing so, we wish to 
examine and assemble the available evidence 
regarding the role of antihypertensive drugs, 
particularly β-blockers in manifestation of ED. 
Additionally, by uncovering the underlying 
causes of ED and exploring the mechanisms by 
which antihypertensive drugs manifest this 
disorder, we may provide information to 
healthcare providers for selecting drugs, having 
safer profile and appropriate dose. This article 
may certainly leave a beneficial impact on clinical 
and pharmaceutical care practices involved in 
effective management of hypertensive patients 




Search strategy  
 
A literature search was conducted on PubMed, 
EMBASE, CINAHL, ProQuest and EBSCO 
Health databases to find all potentially relevant 
publications. The key words used for search 
include: “antihypertensive agents”, “sexual 
dysfunction”, “erectile dysfunction”, “β-blockers” 
and “risk factors”. The reference lists of primary 
original articles and review articles were also 
review so that further relevant studies could be 




Research articles, reviews, editorials, and case 
reports published in English language regarding 
the use of antihypertensive drugs, particularly β-
blockers, and the manifestation of ED were 
included, and the data was then published as 
opinions, commentaries and conference 





One investigator reviewed the papers to evaluate 
potential relevance. The data were drawn from 
the included studies to identify the results of 
investigations indicating the relationship between 
antihypertensive therapy, particularly β-blockers, 
and ED. Additionally, descriptive features and 
data analysis methods were identified that could 
indicate the strength of evidence. The risk 
factors, comorbidities and ED mechanism of 




Prevalence of erectile dysfunction (ED) 
 
The normal population was also found to be 
suffering from ED. A study indicated that twenty 
six person per one thousand were found to suffer 
from ED [9]. Another study indicated that more 
than half of the men's population (52 %), aged 40 
- 70 years, were suffering from some degree of 
ED [10]. An interview-based study conducted by 
psychologist involving 98 sexually active men, 
aged 20 - 35, shows that 8.25 % of the 
respondents reported ED during intercourse and 
18.50 % during masturbation [11]. In addition, a 
study conducted on matrimonially stable couples, 
men age (37.42 ± 11.15 years) and women age 
(35.04 ± 10.07 years), indicated that 7 % men 
failed in achieving an erection and 9 % could not 




ED was found in almost all age groups but the 
incidences were higher in elderly men. A study 
indicated the prevalence of 2 %, 6.7 % and 24 % 
in respondents aged ≤ 40, 55 and 70 years [13]. 
A similar relationship was revealed in another 
study, in which the prevalence was 1 - 10 % in 
younger males (< 40 years), 2 – 9 % in middle 
age (40 - 50 years), 20 – 40 % in older people 
(60 - 69 years) and 50 – 100 % in elderly people 
(> 70 years) [14].  
 
A German population-based study indicated that 
19.2 % ED surged was related to age ( 2.3 - 53.4 
%) and comorbidities like hypertension and 
diabetes [15]. A Turkish population-based study 
indicated 69.2 % age-adjusted overall incidence 
of ED with varying degree of severity (33.2 % 
mild, 27.5 % moderate and 8.5 % severe) [16]. 
This study further indicated that age, lower 
education, unemployment, hypertension, 
diabetes and depression were the contributing 
factors for ED [16]. An age-adjusted prevalence 
of ED in Brazil, Italy, Malaysia and Japan was 
reported to be 15 %, 17 %, 22 % and 34 %, 
respectively [17]. These populations also 
indicated aging, heavy smoking, cardiac 
diseases and diabetes were the other risk factors 
[17]. A Tampere Ageing Male Urological Study 
indicated the relationship of the dysfunction with 
age (mean score increase from 0.82 (50 years) 
to 1.85 (75 years), hypertension (r = 5.1), cardiac 
diseases (r = 6.5), diabetes (r =17.5) and 
smoking (r = 4.6) [18]. An Italian study indicated 
prevalence (19.9 %) and other factors as: higher 
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age (4.6 % in male < 25 years, 37.65 in male > 
74 years), diabetes (Odds ratio (OR) 1.2, 95 % 
Cl 1.1 - 1.4), hypertension (OR 1.3, 95 % Cl 1.1 - 
1.4) and cardiopathy (OR 1.5, 95 % Cl 1.3 - 1.8) 
[19]. A study involving 2869 men in Vienna 
indicated 32.2 % prevalence of ED and high risk 
contributors; diabetes (OR 3.0, 95 % Cl 1.53 - 
5.87), hypertension (OR 2.05, 95 % Cl 1.61 - 
2.6), hyperlipidemia, stress and sedentary 
lifestyle [20].  
 
The first large study to explore the prevalence of 
sexual dysfunction in hypertensive subjects 
“Treatment of Mild Hypertension Study” indicated 
that this disease was considerably low in females 
(4.9 %) compared to males (14.4 %) [21]. 
However, in this study,  mild-hypertensive 
patients and patients of 45 - 69 years were 
included, whereas severe-hypertensive, diabetic 
and elderly patients (> 70 years)  were excluded, 
and only one question was used to  assess the 
disease [21]. A study carried out on 2130 
hypertensive Spanish men indicated 45.8 % 
prevalence, whereas it was 18.5 % in the general 
population [22]. Similarly, a study involving 634 
Greek men indicated that 35.2 % hypertensive 
subjects and 14.1 % normal subjects suffered 
from ED [23]. The manifestation of ED was said 
to be more common in hypertensive population 
compared to that of the normotensives [21-24]. A 
number of studies showed that ED shared many 
risk factors of the cardiovascular diseases such 
as atherosclerosis [25], hypertension, 
hyperlipidemia, diabetes mellitus [26], smoking 
[27], obesity and inactive lifestyle [28]. The 
prevalence of ED in the presence of different 
comorbidities is summarized in Table 1. 
 
Etiology of ED in hypertensive patients and 
probable mechanism 
 
The etiologies of ED in hypertensive patients are 
almost similar to that of the general population. 
There are several social, psychological, 
physiological and drug-related effects that can 
enhance the incidence of the disease. However, 
based on the literature review, etiologies of the 
dysfunction and probable mechanisms by which 
antihypertensive drugs manifest ED are shown in 
Table 2. 
 
      Table 1: Erectile dysfunction (ED) and some risk factors 
 
ED prevalence Risk factor No. of reports [ref] 
33-89 % Aging (>40 years) 8 [29-36] 
27-68 % Hypertension 3 [37-39] 
42-75 % Coronary artery disease 6 [40-45] 
75 % Heart failure 1 [46] 
20-65 % Diabetes mellitus 5 [47-51] 
High prevalence*  Hyperlipidemia 3 [52-54] 
High prevalence*  Smoking 4 [55-58] 
25-90 % Depression and anxiety 1 [59] 
High prevalence* Medication 3 [60-62] 
       *Exact percentage was not reported 
 
Table 2: Etiology of erectile dysfunction (ED) and mechanisms of dysfunction 
 
Etiology Mechanism 
Arterial insufficiency Decreased blood flow toward corpus cavernosum  [4] 
Endothelial dysfunction 
The insufficient vasodilatory response of penile vessels and trabecular smooth 
muscle relaxation because of reduction in nitric oxide availability(NO) derived 
by endothelium [63] 
Depression and anxiety  Decreased sex drive and impairment of NO release [63] 
β-blockers 
Ambiguous mechanism; lower the level of testosterone resulting in the 
decrease in sexual drive and function, and depress Leydig cell’s activity 
involving β2 receptors (although, their role in ED is not clear, they mediate 
vasodilation in response to increases in adrenaline during erection.Therefore, 
non-selective β-blockers increase the possibility of ED [64-66]. Propranolol due 
to its higher lipophilicity enters into the central nervous system and inhibits 
sympathetic stimulation, thus decreasing erection [67]. 
Diuretics 
 1-Aldosterone antagonist 
2-  Thiazide diuretics 
Anti-androgen effect: compete with dihydrotestosterone and testosterone for 
androgen receptor binding sites and weak inhibition of testosterone 
biosynthesis [63].  
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Antihypertensive drugs and ED 
 
The summary of the literature reported regarding 
the involvement of antihypertensive drugs 
particularly β-blockers in ED, study design, 
sample size, drugs used and the major findings 
is given as follows: 
 
The literature has numerous reports regarding 
the relation between ED and β-blockers. A 
multicenter, randomized, placebo-controlled trial, 
recruiting 697 hypertensive patients (21 - 65 
years), taking atenolol and chlorthaildone 
indicated that ED was severe in 11 % 
participants [68]. A prospective, randomized, 
double blind study, conducted on 192 men 
suffering from coronary heart disease, indicated 
that sex life of the subjects was not affected by 
using metoprolol, because ED scores remained 
the same in the drug and placebo groups. 
Around 60 % of the study population had no 
complaints regarding erection and reaching 
orgasm [69].  
 
The effect of carvedilol and valsartan 
(angiotensin-receptor blockers) on sexual activity 
and plasma testosterone was compared in a 
randomized, double blind, crossover study, 
recruiting 160 hypertensive men (40 - 49 years), 
indicated ED in 15 patients taking carvedilol 
(13.5 %), and 1 patient each taking valsartan and 
placebo [70]. In another double blind, parallel 
arm study, conducted on 110 hypertensive men 
(age 40 - 49 years), using valsartan and atenolol 
to evaluate their role on sexual activity and 
testosterone levels indicated that atenolol 
significantly reduced sexual activity (from 6.0 
episodes of sexual intercourse/month to 4.2 
episodes/month vs placebo, p < 0.01), whereas 
valsartan significantly improved sexual function 
compared to atenolol (p < 0.05), but the effect 
was not significant compared to placebo (p = 
0.058) [71]. Silvestri et al [72] carried out a two 
phase study - first phase parallel study and 
second double blind, placebo-controlled, single 
crossover study on 96 men (40 % with angina 
and 60 % hypertension), aged (52 ± 7 years), 
who were well-informed about sexual side effects 
of atenolol and it had been indicated that ED 
incidences were only 3.1 % in a group not 
knowing the drug, 15.6 % in a group knowing the 
drug and 31.2 % in a group aware of the side 
effects of the drug.  
 
A placebo-controlled study involving 134 
hypertensive males using Propranolol and 
Chlorothiazide revealed 11 % cases of 
impotence and 7 % failed ejaculation in 
propranolol group, 14 % impotence and 5 % 
failed ejaculation cases in placebo group and 10 
% impotence and 6 % failed ejaculation cases in 
untreated hypertension group [73]. A multicenter, 
randomized, double blind, clinical trial on 626 
mild to moderate hypertensive men using drugs 
such as captopril, methyldopa, propranolol and 
hydrochlorthiazide indicated that the participants 
taking captopril raised less complaints of ED than 
those taking propranolol [74]. Two case reports 
in the year 1976 indicated that ED in 
hypertensive patients was caused by the use of 
propranolol [75,76]. Warren et al [77] reported 5 
% incidence of sexual dysfunction in a 
prospective follow-up study on 63 patients (49 
men and 11 women) suffering from angina 
prectoris and being treated with Propranolol. In 
another independent study, the same authors 
reported that 5 % incidence of ED was due to the 
use of propranolol [78]. A randomized, double 
blind, crossover study which recruited 40 
hypertensive male patients showed that 18 % 
cases of impotence and 27 % diminished libido 
were in a group consuming propranolol at a dose 
of 320 mg/day [79]. 
 
Two further reports were found which indicate 
that propranolol-induced ED is dose-related. The 
first study [80] conducted on 46 patients with no 
prior ED indicated 15 % cases of complete 
erectile failure (getting mean daily dose of 143 
mg/day) and 28 % cases of  decrease in quality 
of erection (receiving mean daily dose of 124 
mg/day) and  in the second study [79] 
participants receiving a dose of 180 - 320 mg/day 
suffered from complete erectile failure or 
decreased potency, while 57 % of those treated 
with 120 - 160 mg/day reported other complaints 
similar to that of the first study. Interestingly, 
patients taking a mean daily dose of 83 mg/day 
of propranolol did not report any incidence of ED 
[80].  
 
Moreover, in the study of Holliefield et al [79] not 
even a single person out of 40 subjects, 
consuming propranolol 160 mg/day, complained 
of ED; only 2 persons out of 11 (18 %) reported 
complete erectile failure/impotence (taking a 
dose of ≥ 320 mg) and 3 out of 11 (27 %) 
reported a decreased sexual desire. Only one 
study addressed the effect of propranolol upon 
ejaculation and this study revealed 7 % incidence 
of failed ejaculation in hypertensive subjects [73]. 
On the other hand, 6 % of the general 
population, 10 % untreated group and 5 % taking 
placebo, reported the same problem. Hence, 
there was very little support regarding the effects 
of propranolol on ejaculation. 
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The results of this literature survey were stunning 
in a number of aspects. Firstly, the reported 
literature did not support the  involvement of β-
blockers in the manifestation of ED. Secondly, 
we did not find even a single study conducted on 
retrospective data regarding β-blockers-induced 
ED. Almost all of the studies were prospective. 
Its probable cause may be the unavailability of 
sufficient data in the patient’s record needed to 
draw conclusions about the involvement of β-
blockers in the manifestation of ED. Furthermore, 
hypertensive patients taking β-blockers may 
suffer from ED because of psychological factors 
(depression, stress, anxiety, loss of relation and 
known side effects of drugs), co-morbidities, 
adjuvant medication, heavy smoking, obesity and 
sedentary lifestyle. On the other hand, in this 
literature survey, we found concrete evidence 
regarding the involvement of propranolol in the 
manifestation of ED.  
 
However, we did not find any clear mechanism 
which suggested that propranolol caused the 
disease. The involvement of atenolol and 
carvediolol in manifestation of ED was 
controversial, since only one study indicated that 
carvedilol had a negative impact on sexual 
function [70]. Two studies [68,71] revealed that 
ED was caused by atenolol; in the first [68] the 
difference between the two groups, receiving 
atenolol and usual diet and those receiving 
placebo and usual diet was not statistically 
significant (p > 0.05). Contrary to the findings of 
second study [71], Silvestri et al [72] reported 
that the incidence of ED was very high in those 
subjects who were well-informed regarding 
sexual side effects of atenolol than those 
unaware of the given antihypertensive agent 
(31.2 vs 3.1 %). 
 
These findings indicate that awareness of the 
patients regarding the side effects of the drug 
played a contributory role in the manifestation of 
this disorder [72]. In addition, anxiety, stress and 
fear were also reported to be involved in causing 
sexual dysfunctions [81]. Numerous studies 
suggest that anxiety is common amongst 
sufferers of sexual dysfunctions, with varying 
levels and nature of anxiety and anxiety 
reduction procedures improve some aspects of 
sexual dysfunctions [80]. It is suggested that the 
knowledge of side effects produce anxiety that 
may affect sex life or erectile function [72]. 
Therefore, further investigations are required in 
order to understand and clarify the role of β-





Erectile dysfunction (ED) is a widespread 
problem among the hypertensive male 
population and it adversely affects both patient’s 
quality of life and adherence to treatment 
regimen. The reported data do not support the 
conventionally held belief that β-blockers induce 
ED. However, it was evident that the involvement 
of propranolol, if used in higher doses, could 
cause ED and induce ejaculatory disturbances. 
The etiology of ED in hypertensive males is 
multifactorial and may be caused by vascular 
disease, decreased heart capacity, medications 
and/or other factors such as heavy smoking, 
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